Search Results

You are looking at 1 - 10 of 515 items for :

  • "systemic therapy" x
  • Refine by Access: All x
Clear All
Full access

Diane L. Reidy-Lagunes

, liver-directed therapies, and systemic therapies. Cytotoxic therapies, such as temozolomide, fluorouracil, oxaliplatin, and streptozocin-based chemotherapy regimens, are active against some pancNETs, and can play a role in the palliation of patients with

Full access

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

participating institution. For the purposes of this analysis, patients who received intraperitoneal chemotherapy in the first-line setting or who never received systemic therapy were excluded. The database was used to extract information regarding patient

Full access

John A. Thompson

suggest the emergence of a plateau with Figure 1. NCCN recommendations for metastatic or unresectable melanoma: first-line systemic therapy. combination therapy. However, he added, a common side effect (noted in approximately 55% of patients

Full access

Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle, and for the Australia and New Zealand Breast Cancer Trials Group

For women with large or highly proliferative operable breast cancer, the decision about whether to receive neoadjuvant systemic therapy (NAST) is guided by preferences that may lead to individual patients with similar clinical circumstances choosing

Full access

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

RCC in community practice were examined, focusing on systemic therapy. Patients and Methods Data Source and Study Sample NCI Patterns of Care Data: The NCI SEER program collects information on all cancer diagnoses in defined geographic

Full access

Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar, and Youn H. Kim

Cutaneous Lymphomas. Although this article predominantly discusses the role of systemic therapy, skin-directed therapies (eg, topical therapy, phototherapy, involved-site radiation therapy [RT], total skin electron-beam therapy [TSEBT]) also have an

Full access

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

States. The disease is localized to the breast in 62% of patients and to the breast and regional nodes in 30%. 1 Primary preoperative systemic therapy (PST) is commonly used in patients with localized disease with a larger primary tumor or regionally

Full access

Suzanne George

-Farber Cancer Institute. Negative preliminary phase III results led to the removal of olaratumab from the NCCN Guidelines, where it was given in combination with doxorubicin as systemic therapy, while other histology-specific drugs have entered the space and

Full access

Deborah K. Armstrong

disease, secondary debulking is reasonable only when the lesion can be completely excised, but systemic therapy is universally appropriate. Treatment for patients with platinum-resistant disease (platinum-free interval < 6 months) is sequential single

Full access

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

. For patients with BCLC stage C HCC, defined by macrovascular invasion and/or distant metastases, systemic therapy is the historical standard of care. However, for liver-confined BCLC stage C disease or limited extrahepatic spread, LRT can be effective